Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CU-20101 vs Botox in Moderate to Severe Glabellar Lines
NCT06585696Phase 3Completed
- Sponsor
- Cutia Therapeutics
- Start
- Jun 2024
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CU-20101 in glabellar rhytides (2 arms), sponsored by Cutia Therapeutics. Primary endpoint: Proportion of subjects with an FWS score of 0 or 1 and a decrease of >= 2 points from baseline at 4 weeks. Started Jun 2024; status: completed.
02
Drugs
CU-20101
03
Conditions
glabellar rhytides
Beyond the preview
Go deeper on NCT06585696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585696.